ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 教員研究業績
  2. 薬物動態学研究室
  3. 原著論文

HPLCを用いたエンザルタミドおよびその活性代謝物の血漿中濃度測定系の確立

https://gifu-pu.repo.nii.ac.jp/records/14119
https://gifu-pu.repo.nii.ac.jp/records/14119
ed000fa4-271f-43c0-bcaf-bfc79e391238
Item type 研究室原著論文(1)
公開日 2020-05-10
タイトル
タイトル HPLCを用いたエンザルタミドおよびその活性代謝物の血漿中濃度測定系の確立
タイトル
タイトル Development of a HPLC-UV Method for the Quantitative Determination of Enzalutamide and its Active Metabolites in Human Plasma.
言語 en
言語
言語 jpn
キーワード
言語 en
主題Scheme Other
主題 enzalutamide
キーワード
言語 en
主題Scheme Other
主題 N-desmethyl enzalutamide
キーワード
言語 en
主題Scheme Other
主題 HPLC-UV
キーワード
言語 en
主題Scheme Other
主題 prostate cancer
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
抄録
値 Enzalutamide is an orally administered drug that effectively treats castration-resistant prostate cancer. The prescribed dose of enzalutamide in Japan is the same as that in other countries, possibly causing an overdose of enzalutamide and adverse drug reactions (ADRs) in Japanese patients. In the present study, for the pharmacokinetic study to investigate the relationship between the effectiveness/ADRs and the concentrations of enzalutamide, we developed a method to measure plasma concentrations of enzalutamide and its main active metabolite (N-desmethyl enzalutamide) using high performance liquid chromatography (HPLC). The HPLC-UV system used was Shimadzu LC-20Avp equipped with a 5C18 column using 20 mM ammonium acetate (pH5.0) containing 43% acetonitrile as the mobile phase. Enzalutamide and N-desmethyl enzalutamide were detected at 237 nm. Plasma samples were deproteinized by adding acetonitrile containing an internal standard substance (IS), nilutamide. After the centrifugation, the supernatant was collected and evaporated to dryness under a stream of nitrogen gas. The residue was reconstituted with the mobile phase and injected into the HPLC system. Peaks of IS, N-desmethyl enzalutamide and enzalutamide were detected at a retention time of 9.5, 12.7 and 16.8 min, respectively. The established method was validated based on FDA guidelines and found to have good linearity (0.25-25 μg/mL), precision and accuracy. We also confirmed that our method was applicable to the measurement of patient plasma. These results suggest that the established method would be suitable to measure enzalutamide and N-desmethyl enzalutamide in plasma for the research to promote the proper use of enzalutamide.
書誌情報 医療薬学

巻 46, 号 5, p. 257-265, 発行日 2020-05-10
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-19 07:45:36.896889
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3